Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 3/20 | 0.54 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561387 | 0.83 | MAPT (0.70) | ERCC1ERCC4ALDH1A1LMNAGAA | |
| SCHEMBL2318554 | 0.81 | L3MBTL1 (0.58) | ERCC1ERCC4KDM4EALDH1A1LMNA | |
| SCHEMBL28470399 | 0.81 | KMT2A (0.55) | ALDH1A1LMNAGAAHDAC8KMT2A | |
| SCHEMBL1174341 | 0.81 | PKM (0.56) | ERCC1ERCC4KDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11858514 | 0.81 | MAPT (0.68) | ERCC1ERCC4ALDH1A1LMNAGAA | |
| SCHEMBL26333385 | 0.81 | ERCC1 (0.53) | ERCC1ERCC4KDM4EALDH1A1LMNA | |
| SCHEMBL7175504 | 0.80 | PKM (0.54) | ERCC1ERCC4KDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL3069393 | 0.79 | ABAT (0.53) | ERCC1ERCC4KDM4EALDH1A1LMNA | |
| SCHEMBL7785939 | 0.79 | ABAT (0.53) | ERCC1ERCC4KDM4EALDH1A1LMNA | |
| SCHEMBL41828 | 0.79 | ABAT (0.53) | ERCC1ERCC4KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455734-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | Yu, Ruey J., Dr. (US) | 2004-09-15 | — | — | EP | claimed |
| WO-2003045338-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | YU RUEY J (US) | 2003-06-05 | — | — | WO | claimed |
| EP-0030846-A2 | Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1981-06-24 | — | — | EP | claimed |
| CN-116200968-B | Preparation method of white core cardboard for cigarettes | 武汉虹之彩包装印刷有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-116043610-B | Preparation method of cigarette packaging paper | 武汉虹之彩包装印刷有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-116200968-A | Preparation method of white core cardboard for cigarettes | 武汉虹之彩包装印刷有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116043610-A | Preparation method of cigarette packaging paper | 武汉虹之彩包装印刷有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-7928137-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN W | 2007-07-05 | — | — | US | disclosed |
| US-7220781-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-0537255-B1 | PROCESS FOR PREPARATION OF BETA-LACTAMS | DSM IP ASSETS BV (NL) | 2006-02-15 | — | — | EP | disclosed |
| EP-1009758-B1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20040143018-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6740682-B2 | TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. | TULARIK LIMITED (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-05-09 | — | — | US | disclosed |
| EP-1009758-A1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999011658-A1 | META-BENZAMIDINE DERIVATIVES AS SERIN PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
| EP-0537255-A1 | PROCESS FOR PREPARATION OF $g(b)-LACTAMS | GIST-BROCADES B.V. (NL) | 1993-04-21 | — | — | EP | disclosed |
| WO-1992001061-A1 | PROCESS FOR PREPARATION OF β-LACTAMS | NOVO NORDISK A/S (DK) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | ERCC1 4239/4885ERCC4 3451/4885KDM4E 2085/4885 |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | PEPD, SERPINE1, HPN | ERCC1 4674/4885ERCC4 3112/4885KDM4E 1475/4885 |
| US-20040143018-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | ERCC1 4239/4885ERCC4 3451/4885KDM4E 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.